Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1993 1
1994 1
1999 1
2000 1
2001 2
2002 1
2005 1
2007 1
2008 2
2009 1
2011 2
2012 2
2013 1
2014 2
2015 1
2016 1
2017 1
2018 1
2019 2
2020 1
2021 2
2022 4
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Genetically predicted serum testosterone and risk of gynecological disorders: a Mendelian randomization study.
Zhao B, Wang Z, Liu D, Zhang S. Zhao B, et al. Front Endocrinol (Lausanne). 2023 Nov 21;14:1161356. doi: 10.3389/fendo.2023.1161356. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38075074 Free PMC article.
RESULTS: The results showed that total testosterone and bioavailable testosterone were protective factors for ovarian cancer (odds ratio (OR) = 0.885, P = 0.012; OR = 0.871, P = 0.005) and endometriosis (OR = 0.805, P = 0.020; OR = 0.842, P = 0.028) but were risk factors f …
RESULTS: The results showed that total testosterone and bioavailable testosterone were protective factors for ovarian cancer (odds ra …
Practice guideline on ovarian tissue cryopreservation and transplantation in the prevention and treatment of iatrogenic premature ovarian insufficiency.
Ruan X, Xu C, Huang H, Xu B, Du J, Cheng J, Jin F, Gu M, Kong W, Yin C, Wu Y, Tian Q, Cao Y, Wu R, Xu L, Jin J, Li Y, Dai Y, Ju R, Ma F, Wang G, Wei W, Huang X, Qin M, Lin Y, Sun Y, Liu R, Zhang W, Li X, Zou L, Hao M, Ye X, Wang F, Wang Y, Hu Z, Huang Y, Zhu T, Yang C, Wang J, Yang X, Ni R, Wang L, Luo G, Min A, Zhang S, Li P, Cheng L, Li L, Jin Q, Shi D, Li Y, Ren F, Cheng Y, Niu J, Tian Y, Mueck AO. Ruan X, et al. Maturitas. 2024 Apr;182:107922. doi: 10.1016/j.maturitas.2024.107922. Epub 2024 Jan 26. Maturitas. 2024. PMID: 38325136 Free article.
Premature ovarian insufficiency (POI) refers to the decline of ovarian function before the age of 40. ...International and national guidelines consider cryopreserved ovarian tissue transplantation to be the most promising method of preserving the ov …
Premature ovarian insufficiency (POI) refers to the decline of ovarian function before the age of 40. ...International …
Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study.
Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, Yasui Y. Green DM, et al. J Clin Oncol. 2009 May 10;27(14):2374-81. doi: 10.1200/JCO.2008.21.1839. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364956 Free PMC article. Review.
These studies were undertaken to determine the effect, if any, of treatment for cancer diagnosed during childhood or adolescence on ovarian function and reproductive outcomes. We reviewed the frequency of acute ovarian failure, premature menopause …
These studies were undertaken to determine the effect, if any, of treatment for cancer diagnosed during childhood or adolescence on ovari …
Evaluation of ovarian reserve in young females with non-iatrogenic ovarian insufficiency to establish criteria for ovarian tissue cryopreservation.
Zajicek M, Volodarsky-Perel A, Shai D, Dick-Necula D, Raanani H, Gruber N, Karplus G, Kassif E, Weisz B, Meirow D. Zajicek M, et al. Reprod Biomed Online. 2023 Jul;47(1):102-109. doi: 10.1016/j.rbmo.2023.03.004. Epub 2023 Mar 12. Reprod Biomed Online. 2023. PMID: 37120360
RESEARCH QUESTION: Can ovarian reserve parameters predict the outcome of ovarian tissue cryopreservation (OTCP) in patients 18 years with non-iatrogenic premature ovarian insufficiency (POI)? ...Fourteen (11 aged 12 years and 3 aged <12) underwent O …
RESEARCH QUESTION: Can ovarian reserve parameters predict the outcome of ovarian tissue cryopreservation (OTCP) in patients 18 …
Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer.
Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Vini L, et al. Postgrad Med J. 2002 Feb;78(916):92-3. doi: 10.1136/pmj.78.916.92. Postgrad Med J. 2002. PMID: 11807191 Free PMC article. Review.
Transient amenorrhoea or menstrual irregularities lasting up to 10 months were experienced in 83 patients (17%). No cases of permanent ovarian failure were recorded. There were 427 children born to 276 women; only one patient wishing to achieve a successful pregnanc …
Transient amenorrhoea or menstrual irregularities lasting up to 10 months were experienced in 83 patients (17%). No cases of permanent ov …
Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
Nourmoussavi M, Pansegrau G, Popesku J, Hammond GL, Kwon JS, Carey MS. Nourmoussavi M, et al. Cancer Treat Rev. 2017 Apr;55:26-35. doi: 10.1016/j.ctrv.2017.02.005. Epub 2017 Feb 22. Cancer Treat Rev. 2017. PMID: 28288389 Review.
Historically, ovarian ablation (OA) was used as therapy for women with recurrent hormone-receptor-positive (HRP) premenopausal breast cancer. ...Thus, we have reviewed current guidelines and key studies on this important topic and have highlighted the relevant biolo …
Historically, ovarian ablation (OA) was used as therapy for women with recurrent hormone-receptor-positive (HRP) premenopausal …
MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty.
Guaraldi F, Beccuti G, Gori D, Ghizzoni L. Guaraldi F, et al. Eur J Endocrinol. 2016 Mar;174(3):R79-87. doi: 10.1530/EJE-15-0590. Epub 2015 Oct 14. Eur J Endocrinol. 2016. PMID: 26466612 Review.
GnRH analogues (GnRHa) are the treatment of choice for central precocious puberty (CPP), with the main objective to recover the height potential compromised by the premature fusion of growth cartilages. The aim of this review was to analyze long-term effects of GnRHa on he …
GnRH analogues (GnRHa) are the treatment of choice for central precocious puberty (CPP), with the main objective to recover the height poten …
Risk of premature menopause after treatment for Hodgkin's lymphoma.
Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister A, Lucraft HH, Radford J, Stevens AM, Syndikus I, Williams MV; England and Wales Hodgkin Lymphoma Follow-up Group. Swerdlow AJ, et al. J Natl Cancer Inst. 2014 Aug 19;106(9):dju207. doi: 10.1093/jnci/dju207. Print 2014 Sep. J Natl Cancer Inst. 2014. PMID: 25139687
BACKGROUND: Modern treatment of Hodgkin's lymphoma (HL) has transformed its prognosis but causes late effects, including premature menopause. Cohort studies of premature menopause risks after treatment have been relatively small, and knowledge about th …
BACKGROUND: Modern treatment of Hodgkin's lymphoma (HL) has transformed its prognosis but causes late effects, including premature …
National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Panel. J Natl Cancer Inst Monogr. 2001;(30):5-15. J Natl Cancer Inst Monogr. 2001. PMID: 11773285 Review.
OBJECTIVE: Our goal was to provide health-care providers, patients, and the general public with an assessment of currently available data regarding the use of adjuvant therapy for breast cancer. ...Quality of life needs to be evaluated in selected randomized clinica …
OBJECTIVE: Our goal was to provide health-care providers, patients, and the general public with an assessment of currently available …
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, Mayer R, Roter D. Eifel P, et al. J Natl Cancer Inst. 2001 Jul 4;93(13):979-89. doi: 10.1093/jnci/93.13.979. J Natl Cancer Inst. 2001. PMID: 11438563 Review.
OBJECTIVE: Our goal was to provide health-care providers, patients, and the general public with an assessment of currently available data regarding the use of adjuvant therapy for breast cancer. ...Quality of life needs to be evaluated in selected randomized clinica …
OBJECTIVE: Our goal was to provide health-care providers, patients, and the general public with an assessment of currently available …
35 results